A Randomized Study on Postrelapse Disease-Free Survival with Adjuvant Mistletoe versus Oral Etoposide in Osteosarcoma Patients

Background. Osteosarcoma is a highly malignant bone tumour. After the second relapse, the 12-month postrelapse disease-free survival (PRDFS) rate decreases below 20%. Oral Etoposide is often used in clinical practice after surgery as an “adjuvant” outside any protocol and with only limited evidence...

Descripción completa

Detalles Bibliográficos
Autores principales: Longhi, Alessandra, Reif, Marcus, Mariani, Erminia, Ferrari, Stefano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3988743/
https://www.ncbi.nlm.nih.gov/pubmed/24803944
http://dx.doi.org/10.1155/2014/210198

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3988743/
https://www.ncbi.nlm.nih.gov/pubmed/24803944
http://dx.doi.org/10.1155/2014/210198

Ejemplares similares